MiMedx Group (NASDAQ:MDXG) had its price target lowered by analysts at Lake Street Capital from $12.00 to $10.00. They now have a "buy" rating on the stock.
Recent 8.9% pullback isn't enough to hurt long-term MiMedx Group (NASDAQ:MDXG) shareholders, they're still up 70% over 3 years [Yahoo! Finance]
MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel [Yahoo! Finance]
MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel
With 47% stake, MiMedx Group, Inc. (NASDAQ:MDXG) seems to have captured institutional investors' interest [Yahoo! Finance]